News & Events

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John

More News

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

IND accepted for phase 2 clinical trial in DBA patients; study is expected to initiate mid-year 2023 WATERTOWN, Mass., March 21, 2023...

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

WATERTOWN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) — Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

WATERTOWN, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development...